Overview of Prostaglandin E2

Property	Description
Active ingredient	Dinoprostone (PGE₂)
Forms	Vaginal Insert, Vaginal Suppository, Vaginal Gel, Endocervical Gel
Pharmacological class	Prostaglandin Analog, Oxytocic Agent
General purpose	To promote cervical readiness and uterine activity
Origin	Synthetic, mimicking a naturally occurring lipid signaling molecule

What is Dinoprostone? Identity, Class, and Origin

Dinoprostone is the official non-proprietary name for the active ingredient that is chemically identical to the naturally occurring lipid signaling molecule, Prostaglandin E2 (PGE₂). It is a synthetic compound classified as both a Prostaglandin Analog and a potent Oxytocic Agent (Uterotonic Agent). This classification confirms the substance is designed specifically to initiate changes in the uterine system. The drug is manufactured to replicate the biological activity of the PGE₂ that the human body generates naturally as a member of the eicosanoid family, binding to specific E-type Prostanoid receptors. This therapeutic action is described for its role in modifying the lower uterine segment.

Forms of Prostaglandin E2 and General Purpose

The medication is available in several specialized, single-ingredient dosage form(s) intended for localized delivery, including the Vaginal Insert, Vaginal Suppository, and various viscous formulations such as the Vaginal Gel or Endocervical Gel. These distinct forms utilize the Vaginal or Endocervical routes of administration. The overall purpose of administering Dinoprostone is to modify the state of the cervix and uterus to promote readiness for delivery. Dinoprostone is used to improve the status of the cervix (cervical ripening) and stimulate the uterus, facilitating the overall process. This means the medication helps the cervix soften and thin while also encouraging the uterine muscles to contract, supporting a typical use scenario such as preparing a patient for the planned induction of labor near term.

What side effects are possible with Prostaglandin E2?

The official regulatory safety profile of Dinoprostone (Prostaglandin E2) is strictly characterized by its primary action as an oxytocic agent, with adverse effects classified by frequency and System-Organ Class (SOC) in documents like the EMA SmPC and FDA Prescribing Information.

Adverse Reactions by Frequency and System

The most frequent adverse reactions are related to the drug's effect on the uterus and the resulting impact on the fetus.

Common adverse reactions (ge 1/100 to < 1/10) include uterine hyperstimulation (abnormal contractions), fetal heart rate disorder, and common systemic effects such as nausea, vomiting, and fever (pyrexia).
Uncommon reactions (ge 1/1000 to < 1/100) include hypotension and postpartum haemorrhage.

These effects fall primarily into the Pregnancy, puerperium and perinatal conditions and Gastrointestinal disorders SOC categories.

Serious Adverse Reactions and Safety Constraints

Regulatory labeling highlights specific serious adverse reactions, often classified as rare or of unknown frequency from post-marketing surveillance.

Documented serious events include Uterine Rupture, Anaphylactic Reaction, Amniotic Fluid Embolism, and Disseminated Intravascular Coagulation (DIC), the latter being reported as rare.
Official documents define an increased risk of post-partum DIC in specific populations, including women aged 35 years or older or those with a gestational age over 40 weeks.

The essential safety constraint is the mandated requirement for continuous and careful monitoring of uterine activity and fetal condition. Regulatory documents require the immediate discontinuation of the drug upon signs of uterine hyperstimulation or significant changes in the fetal heart rate pattern to mitigate potential for severe complications.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdosage of Dinoprostone (Prostaglandin E2) is documented in regulatory sources to result primarily in uterine hyperstimulation or uterine hypertonus, which involves contractions that are too frequent, intense, or sustained. This excessive uterine activity is a critical finding that can quickly lead to signs of fetal distress, including changes in the fetal heart rate, which signals an urgent need for medical intervention.

Required Emergency Actions

Regulatory labeling explicitly states that if overdosage is suspected or if evidence of uterine hyperstimulation is observed, the dosage form must be immediately removed or discontinued. Immediate medical attention or contact with emergency services is required for any suspected overdosage. Management, as described in official documents, focuses on symptomatic and supportive care, including continuous electronic monitoring of both uterine activity and fetal status. A tocolytic agent may be administered to relax the uterus and reduce hypertonicity.

Documented Severe Outcomes

The excessive uterine activity associated with overdose can escalate to life-threatening outcomes. Officially documented severe risks include uterine rupture, significant uterine haemorrhage, and the potential for foetal and neonatal death. Furthermore, regulators note an increased risk for Disseminated Intravascular Coagulation (DIC) in pharmacologically induced labor, particularly in women aged 35 years or older or those with a gestational age over 40 weeks.

Therapeutic Uses of Prostaglandin E2

Dinoprostone is commonly used across domains where short-term symptom management is appropriate in obstetrics, in situations involving certain distressing symptoms.

Dinoprostone is relevant for easing symptoms linked to organ-specific functional stress by playing a role in managing heightened physiological activity. It is applied across domains where additional symptomatic support is needed, primarily for two critical obstetric situations: facilitating cervical ripening for labor induction and managing heightened physiological activity in contexts involving the evacuation of uterine contents.

Quick Fact: Relief for Uterine Functional Stress

This medication provides support that helps ease the overall symptom burden when conditions present with acute episodes, such as when labor induction is medically indicated. It assists with maintaining functional stability and contributes to easing the overall symptom load during symptomatic periods.

“This medication is applied in settings marked by temporary physiological imbalance where short-term symptomatic assistance is needed.”

Regulatory References

NIH MedlinePlus overview

Eligibility and Restrictions for Use

Eligibility for Prostaglandin E2 (Dinoprostone)

The official regulatory profile defines eligibility for Dinoprostone (Prostaglandin E2) based strictly on maternal status and pre-existing conditions. The medication is indicated for use in women of reproductive age who are pregnant, specifically for cervical ripening or the evacuation of uterine contents in appropriate clinical situations.

Populations for whom use is contraindicated

Use is strictly prohibited (contraindicated) for patients with a known hypersensitivity to prostaglandins or a history of Cesarean section or major uterine surgery, due to the risk of uterine rupture. Contraindications also apply when there is unexplained vaginal bleeding, fetal distress where delivery is not imminent, or obstetric conditions that prohibit vaginal delivery (e.g., placenta previa). Furthermore, specific formulations are contraindicated in the presence of active cardiac, pulmonary, renal, or hepatic disease.

Eligibility-Related Restrictions

Cautionary use is required for populations with a history of certain systemic conditions, including asthma, glaucoma, or epilepsy, or compromised renal or hepatic function. Additionally, women aged 35 years or older or those with a gestational age over 40 weeks require special consideration due to an officially documented increased risk of postpartum coagulation complications. Use is not established or not applicable in pediatric or older adult populations. During lactation, the use status requires officially weighing the potential maternal benefit against the risk to the infant.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Dinoprostone (Prostaglandin E2) has a highly specific interaction profile, defined primarily by its potent activity as a uterine stimulant, or Oxytocic Agent. The officially documented interaction patterns are almost exclusively limited to pharmacodynamic effects with other medicines that affect the uterus.

Official Interaction Restrictions

Classification	Constraint
Contraindicated Combination	Concurrent administration with Intravenous Oxytocic Agents is formally prohibited by regulatory bodies, including the FDA and EMA.
Pharmacodynamic Augmentation	Dinoprostone may augment or potentiate the activity of other Oxytocic Agents, such as Oxytocin, due to a synergistic effect on uterine contractility.

Administration Timing Separation

The regulatory profile mandates precise timing constraints for sequential administration. The Dinoprostone vaginal insert must be removed for a minimum of 30 minutes prior to the intended administration of any subsequent intravenous oxytocic agent, as stipulated in the official prescribing information.

Pharmacokinetic and Substance Interactions

Official regulatory documents do not contain explicit statements regarding clinically significant metabolic interactions, such as those involving CYP450 enzymes or drug transport proteins (e.g., P-gp). Furthermore, specific interactions with food, alcohol, or herbal products are not documented in the official prescribing information.

Mechanism of Action

Dual Action via E-Prostanoid Receptor Agonism

Dinoprostone, which is chemically identical to naturally occurring Prostaglandin E2 (PGE₂), initiates its effect by acting as a full agonist across the family of E-Prostanoid (EP) receptors (EP1, EP2, EP3, EP4). These receptors are differentially expressed in the uterine muscle cells and the structural cells of the cervix, a characteristic that results in the engagement of two distinct biological processes simultaneously. This receptor-mediated signaling drives both the increase in muscle activity and the alteration of tissue structure.

Activation of Myometrial Calcium Signaling for Contraction

Specific receptor subtypes, primarily EP3, activate the Gq protein pathway, leading to a rapid surge in intracellular calcium ( Ca^2+) within the uterine smooth muscle cells. This increase in Ca^2+ is the molecular trigger for Myosin Light-Chain Kinase activation, which translates directly into increased myometrial smooth muscle tone and coordinated contractile activity.

Biochemical Remodeling of the Cervical Extracellular Matrix

Other receptor subtypes, mainly EP2 and EP4, activate a separate Gs protein-coupled pathway that increases cyclic AMP ( cAMP) signaling within cervical fibroblasts. This cascade promotes the activity of Matrix Metalloproteinases ( MMPs), which are enzymes that target and degrade the dense collagen and proteoglycan fibers in the tissue's extracellular matrix. The result is the physiological consequence of cervical softening and effacement (shortening).

Dosage and Administration Information

How Dinoprostone (Prostaglandin E2) is Used

Dinoprostone is administered under highly controlled conditions within a healthcare setting. This medicine is primarily available in specialized forms for localized delivery.

Official Administration Routes and Dosage

The most common forms require intravaginal or endocervical administration. The medicine is not available for general consumer use.

Form and Route	Standard Dose	Frequency and Duration Constraint
Vaginal Insert (Intravaginal)	Single 10 mg dose	Remains in place for up to 12 hours
Endocervical Gel (Intracervical)	Initial dose of 0.5 mg	May be repeated every 6 hours. Maximum cumulative dose is 1.5 mg in 24 hours
Vaginal Suppository (Intravaginal)	20 mg dose	Subsequent doses administered every 3 to 5 hours

Procedural and Timing Requirements

Administration occurs in a hospital or clinic setting with continuous access to specialized obstetrical care. The patient must remain in a recumbent position for a specified period after placement (e.g., 10 minutes to 2 hours, depending on the form). Continuous monitoring of the patient's status is required throughout the administration period.

Timing constraints also govern the use of subsequent oxytocic agents. The Dinoprostone product must be removed, and a mandatory waiting interval must pass before administering drugs such as oxytocin. This interval varies by product, ranging from 30 minutes for the insert to 6 to 12 hours for other forms, to avoid excessive uterine response. The safety and efficacy of Dinoprostone have not been established for use in patients under 18.

Recent Clinical Evidence

Research evidence / Overview of studies for Prostaglandin E2

Evidence for Use in Labor Induction and Cervical Ripening

The body of research examining Dinoprostone (Prostaglandin E2) in labor induction includes Randomized Controlled Trials (RCTs) and comprehensive Systematic Reviews that combine the results from many individual studies. Research explored the use of the medication in pregnant patients at or near term who had a medical reason for labor to be started. These studies monitored several key outcomes, including changes in the cervix's readiness (often measured using the Bishop Score), the rate of vaginal delivery, and the overall time interval required to achieve delivery.

Findings describe patterns observed where studies tracked metrics like the percentage of patients delivering vaginally within a specific short-term period, such as 24 hours. Research also monitored the requirement for other interventions, such as the use of additional oxytocin. The research has limited power to detect differences in rare maternal or neonatal outcomes between study groups.

Evidence for Use in Therapeutic Uterine Evacuation

Dinoprostone was evaluated in clinical trials and observational studies for its use in specific situations where the evacuation of uterine contents is medically necessary, such as in cases of missed abortion or intrauterine fetal death. Studies measured the completeness of the procedure, with findings describing measurements of the time duration required for the contents to be expelled. Data show patterns related to the expulsion process measured during the studies.

Evidence for this specific indication includes foundational clinical data gathered during the initial regulatory evaluation period. The available research generally provides insight into acute changes related to the immediate expulsion, but long-term effects are not fully established.

Research Gaps and Areas of Uncertainty

One major gap is the limited information for long-term outcomes, as the research primarily observes responses over defined time intervals related to the immediate procedure. Comparative studies are limited when examining this medication against certain other agents, as much of the foundational data was observed in earlier studies. The findings describe group patterns, not personal outcomes, and research does not determine whether an individual will respond similarly.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Prostaglandin E2 (FAQ)

Q: Is Prostaglandin E2 considered a hormone or a drug?

The active ingredient in this medicine is chemically identical to the body's natural Prostaglandin E2 (PGE₂), which is a lipid signaling molecule sometimes described as functioning like a local hormone. However, the product administered as a medicine is a synthetic version officially classified by regulatory bodies as a drug and a potent Oxytocic Agent.

Q: What are the signs to look out for that are considered serious reactions?

Regulatory documents highlight serious, though rare, risks like Anaphylactic Reaction (a severe allergic reaction) and Uterine Rupture. Signs of a serious allergic reaction can include hives, rash, trouble breathing, or swelling of the face. The management of these risks necessitates continuous and careful monitoring by healthcare professionals during treatment.

Q: How quickly does Prostaglandin E2 start to work?

Official product information indicates that for certain formulations, the drug's metabolite reaches its peak concentration in the body in approximately 30 to 45 minutes after it is administered. Other forms, such as the controlled-release insert, are specifically designed to release the medicine gradually over a longer period, such as up to 12 hours.

Q: What is the expected duration of action of Prostaglandin E2?

The active drug molecule itself is designed to be very rapidly metabolized by the body, with the estimated half-life (the time it takes for half the drug to be eliminated) being only a few minutes. However, the product is formulated to provide a prolonged local effect that lasts for several hours.

Q: What happens to Prostaglandin E2 in the body after it has been used?

According to official clinical pharmacology data, the drug is completely and extensively metabolized (broken down) once it begins to be metabolized. This breakdown occurs primarily in the lungs, liver, and kidneys. The resulting metabolic products are then eliminated from the body mainly through the kidneys (in the urine).

Q: Is Prostaglandin E2 approved by regulatory bodies like the FDA or EMA?

Yes, the medicine, known by its non-proprietary name Dinoprostone, is approved and regulated by major governmental drug authorities worldwide. These include the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for its specific, indicated uses.

Q: Why are there different formulations of Prostaglandin E2 (e.g., gel, insert)?

Official product characteristics show the different forms, such as the gel and the insert, are designed to deliver the medicine in specific ways. These different formulations help to control the release profile of the active ingredient and ensure it targets the correct area of administration. The insert, for instance, provides a slow, controlled release over an extended period.

Q: What is the shelf life of the different Prostaglandin E2 products?

The maximum shelf life and expiration date for each specific Prostaglandin E2 product are strictly defined by the manufacturer and printed on the original, unopened packaging. The drug's stability requires strict adherence to the specific temperature requirements listed (which may be refrigerated or frozen, depending on the form) until it is used.

Q: How is Prostaglandin E2 different from Prostaglandin E1?

Prostaglandin E2 (Dinoprostone) and Prostaglandin E1 (Misoprostol) are two distinct prostaglandin analogs. Official regulatory bodies have approved Dinoprostone specifically for uses like cervical ripening and labor induction. Misoprostol (PGE₁) is sometimes used in clinical practice for similar purposes, but may be used off-label (meaning the regulatory body has not approved it for that specific use).

Q: How long do mild side effects usually last after using Prostaglandin E2?

Official patient information indicates that most common, mild side effects, such as a fever or gastrointestinal discomfort, are usually temporary. Since the drug is administered for a short duration and is rapidly cleared, these transient effects typically resolve quickly once the product is removed or the treatment is complete.

Q: Does Prostaglandin E2 interact with NSAIDs (like ibuprofen or aspirin)?

Regulatory resources note that nonsteroidal anti-inflammatory medicines (NSAIDs), such as ibuprofen, may potentially affect the outcome of Dinoprostone treatment. Official prescribing information notes that healthcare providers consider the potential for pharmacodynamic interactions with NSAIDs, which could reduce the efficacy of the drug.

Q: Does the effect of Prostaglandin E2 wear off gradually?

The clinical effect's decline is influenced by the specific formulation used. The active drug molecule is rapidly cleared from the bloodstream. However, because it is administered locally, the overall clinical effect is maintained until the product is fully removed from the administration site or the drug is locally depleted.

Q: Are there ongoing clinical trials examining new uses for Prostaglandin E2?

Yes, studies continue to be registered on official government databases like ClinicalTrials.gov that track ongoing research. These trials examine different ways of using Prostaglandin E2 in labor induction protocols and for potential new applications, such as cervical preparation for various gynecological procedures.

Q: Does using Prostaglandin E2 typically cause localized discomfort?

Official adverse reaction data indicates that localized effects have been reported by patients. These may include vaginal irritation or discomfort at the site of administration. Additionally, in some cases, swelling of the genital area (vulva) has been noted as a potential adverse reaction.

How should Prostaglandin E2 be stored and disposed of?

How to Store and Dispose of Prostaglandin E2

Storage requirements for Prostaglandin E2 (Dinoprostone) are formulation-dependent and strictly defined by official labeling.

Official Storage and Disposal Requirements

Component	Regulatory Requirement
Temperature (Vaginal Insert)	Store frozen at -10 C to -25 C in the original sealed foil sachet. Do not thaw prior to use.
Temperature (Sterile Solution)	Store refrigerated at 2 C to 8 C.
Stability (Dilution)	Diluted Sterile Solution must be refrigerated and used within 24 hours.
Handling	Use caution to prevent skin contact. Keep out of the sight and reach of children.
Disposal	Dispose of unused product according to local regulations; do not discard via household waste or wastewater.

These conditions define how the product must be protected to maintain stability. Disposal mandates adherence to local controlled-waste procedures, prohibiting environmental release.

Prostaglandin E2